drugset / Trial / NCT02953860
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Phase 2
Completed
32 enrolled
University of Colorado, Denver
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and Her2 normal.
Timeline
- Start
- 2017-07-06
- Primary completion
- 2019-11-21
- Completion
- 2020-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |